No­var­tis, Eli Lil­ly mar­quee pos­i­tive sur­vival da­ta for CDK 4/6 fran­chis­es — but can they ac­tu­al­ly beat Pfiz­er's block­buster?

BARCELONA — A lit­tle more than a year af­ter Pfiz­er’s big CDK 4/6 can­cer drug block­buster Ibrance failed to hit the mark in over­all sur­vival, two big ri­vals are knock­ing on their front door bear­ing da­ta from two Phase III stud­ies clear­ly show­ing that their ri­val treat­ments can sig­nif­i­cant­ly ex­tend the lives of pa­tients.

Re­search teams for both turned up at ES­MO over the week­end with promis­ing OS re­sults in ad­vanced breast can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.